remdesivir - versus control - for COVID 19 all comers pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.70 [0.47, 1.04]< 10%1 study (1/-)96.1 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 0.70 [0.47, 1.04]< 10%1 study (1/-)96.1 %some concernnot evaluable moderatecrucial-
clinical improvement 1.32 [1.12, 1.55]> 10%1 study (1/-)100.0 %some concernnot evaluable moderateimportant-

safety endpoints 00

serious adverse events 0.72 [0.54, 0.96]< 10%1 study (1/-)98.8 %some concernnot evaluable moderateimportant-
deep vein thrombosis 0.64 [0.23, 1.81]< 10%1 study (1/-)80.0 %some concernnot evaluable moderatenon important-
elevated liver enzymes 0.67 [0.38, 1.18]< 10%1 study (1/-)91.8 %some concernnot evaluable moderatenon important-
hyperbilirubinemia 0.84 [0.30, 2.34]< 10%1 study (1/-)62.9 %some concernnot evaluable moderatenon important-
pulmonary embolism 0.96 [0.19, 4.80]< 10%1 study (1/-)51.7 %some concernnot evaluable moderatenon important-
renal impairment 1.02 [0.64, 1.61]< 10%1 study (1/-)47.2 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.